Status:
COMPLETED
Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders
Lead Sponsor:
Medical University of Vienna
Conditions:
Hepatitis C
Eligibility:
All Genders
19-70 years
Phase:
PHASE2
Brief Summary
By chance the investigators found that iv. silibinin has a potent antiviral effect against the hepatitis C virus. Based on the results of the dose finding study (published) te optima dosing schedule i...
Detailed Description
Since the publication of the first data the optimal dosing schedule is investigated
Eligibility Criteria
Inclusion
- Nonresponders to full dose PEG-IFN/RBV therapy
- Liver biopsy within the last 2 year
Exclusion
- Intolerance to one of the study drugs
- Coinfection with HIV/HBV
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00684268
Start Date
October 1 2007
End Date
June 1 2011
Last Update
March 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, A1090